Tag archive
Patients with MC4R‑deficient obesity lose only about 12% on semaglutide, far less than expected. A five‑step dosing fix can bridge that gap and restore full wei
In 2026 semaglutide titration delivers about 5.5% loss while tirzepatide pushes results to 15%. Find out which protocol suits rare MC4R deficiency and why the d
Six weeks in, 65% of MC4R‑deficient patients lose at least 10% of body weight—yet semaglutide falls short. Discover the genetic hurdle and the next‑gen drugs re
New data shows retatrutide may cut hypertension and liver enzyme spikes better than tirzepatide for rare MC4R‑deficient obesity. Discover the seven ways it beat